[
    {
        "patient_id": "d8c5da9e-b4cb-4be7-aca2-b257ed16a6b0",
        "drug": "CODEINE",
        "timestamp": "2026-02-19T20:23:12.649874838Z",
        "risk_assessment": {
            "riskLabel": "Safe",
            "confidenceScore": 0.95,
            "severity": "none"
        },
        "pharmacogenomic_profile": {
            "primary_gene": "CYP2D6",
            "diplotype": "*1/*2",
            "phenotype": "NM",
            "detected_variants": [
                {
                    "rsid": "rs16947",
                    "star_allele": "*2",
                    "genotype": "0/1"
                }
            ]
        },
        "clinical_recommendation": {
            "action": "Proceed with standard dosing",
            "recommendation": "Codeine can be used at standard doses. No dose adjustment required.",
            "monitoring": "Standard pain reassessment at follow-up."
        },
        "llm_generated_explanation": {
            "summary": "Explanation unavailable — pharmacogenomic profile and risk assessment are provided in the structured fields above."
        },
        "quality_metrics": {
            "vcf_parsing_success": true
        }
    },
    {
        "patient_id": "d8c5da9e-b4cb-4be7-aca2-b257ed16a6b0",
        "drug": "WARFARIN",
        "timestamp": "2026-02-19T20:23:12.649874838Z",
        "risk_assessment": {
            "riskLabel": "Adjust Dosage",
            "confidenceScore": 0.95,
            "severity": "moderate"
        },
        "pharmacogenomic_profile": {
            "primary_gene": "CYP2C9",
            "diplotype": "*1/*2",
            "phenotype": "IM",
            "detected_variants": [
                {
                    "rsid": "rs1799853",
                    "star_allele": "*2",
                    "genotype": "0/1"
                }
            ]
        },
        "clinical_recommendation": {
            "action": "Reduce initial warfarin dose by 25–50%",
            "recommendation": "Reduced CYP2C9 activity will slow warfarin clearance. Initiate at 25–50% of standard dose to avoid supratherapeutic INR.",
            "monitoring": "Increase INR monitoring frequency: days 3, 5, 7, 10. Target INR 2.0–3.0."
        },
        "llm_generated_explanation": {
            "summary": "Explanation unavailable — pharmacogenomic profile and risk assessment are provided in the structured fields above."
        },
        "quality_metrics": {
            "vcf_parsing_success": true
        }
    }
]